Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Licensing opportunity from NIH: geldanamycins as inhibitors of the HGF/SF-Met pathway

Sep. 3, 1999

IGT-13, a new and improved etoposide analogue enters the IGT pipeline

Sep. 2, 1999

More ACS news: preclinical profile of a novel protein farnesyltransferase inhibitor, Sch-207758

Sep. 2, 1999

New Roche compounds enhance tumor delivery of 5-FU

Sep. 2, 1999

Cytoclonal makes strides in the design of new anticancer compounds

Sep. 2, 1999

Preparation, activity and use of piperidine protein farnesyltransferase inhibitors from LG Chemical

Sep. 2, 1999

Scotia's Foscan achieves positive results in phase III clinical trial

Sep. 1, 1999

New anticancer compound from Diatide shown to arrest tumor growth

Sep. 1, 1999

Progen receives provisional approval to undertake clinical studies of PI-88 at second site

Sep. 1, 1999

DuPont team presents new cdk inhibitors at ACS meeting

Aug. 31, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...